Next Article in Journal
Cognitive Flexibility in Hospitalized Patients with Severe or Extreme Anorexia Nervosa: A Case-Control Study
Next Article in Special Issue
Effect of Arabic Qahwa on Blood Pressure in Patients with Stage One Hypertension in the Eastern Region of Saudi Arabia
Previous Article in Journal
MGMT Promoter Methylation: Prognostication beyond Treatment Response
Previous Article in Special Issue
Etiological Diagnosis and Personalized Therapy for Hypertension: A Hypothesis of the REASOH Classification
 
 
Article
Peer-Review Record

Cost-Effectiveness Analysis of Personalized Hypertension Prevention

J. Pers. Med. 2023, 13(6), 1001; https://doi.org/10.3390/jpm13061001
by Sen-Te Wang 1,2, Ting-Yu Lin 3, Tony Hsiu-Hsi Chen 3, Sam Li-Sheng Chen 4,* and Jean Ching-Yuan Fann 5,*
Reviewer 1:
Reviewer 2: Anonymous
J. Pers. Med. 2023, 13(6), 1001; https://doi.org/10.3390/jpm13061001
Submission received: 14 May 2023 / Revised: 9 June 2023 / Accepted: 9 June 2023 / Published: 15 June 2023
(This article belongs to the Special Issue Personalized Medicine in Hypertension)

Round 1

Reviewer 1 Report

Dear Author/s, 

I read your article carefully. Your article explores the cost-effectiveness of a personalized approach to preventing hypertension, combining lifestyle changes and pharmacological intervention. The study found that the personalized preventive strategy was more cost-effective compared to standard care. I hope your findings help policymakers to attention more to prevention than treatment.

Good Luck

Author Response

Thank you for your kind words and comments.

Reviewer 2 Report

The authors presented a research on the cost-effectiveness analysis of personalized hypertension prevention. No major concerns were noticed by the reviewer. Minor issues include:

1. Will the authors include more literature review on the cost-effectiveness analysis of hypertension prevention and other major diseases in the introduction.

2. Will the cost-effectiveness analysis results differ across different demographic characteristics and other epidemiological characteristics.

Author Response

Q(1) Will the authors include more literature review on the cost-effectiveness analysis of hypertension prevention and other major diseases in the introduction.

Ans: Thank you for your valuable comments. We have added more literature reviews on the cost-effectiveness of hypertension prevention studies. (Page 2, Line 14-29)

 

Q(2) Will the cost-effectiveness analysis results differ across different demographic characteristics and other epidemiological characteristics.

Ans: Thank you very much for your insightful remark. Our suggested tailored preventative strategy is based on risk stratification, which already takes into account demographic and other epidemiological characteristics. Therefore, we think these considerations may have an impact on the absolute values but won't have a big effect on the cost-effectiveness results.

Back to TopTop